The licensed “slimming pill” that gives 15% weight loss arrives in Spain
In recent days the so-called “slimming pill” has arrived in Spain, a drug developed to be used against cardiovascular risk factors such as hypertension, hypercholesterolemia or type 2 diabetes, all associated with the rise of this problem related to lifestyle and diet, but is also used to combat obesity, which is not a contagious disease but the most widespread metabolic problem of our time.
Semaglutide is already approved in Spain as a drug for the treatment of complicated diabetes, but it is also approved as a treatment for obesity in the United States and, provisionally, in the United Kingdom.
It is a drug from the GLP-1 group of drugs, most of which are used in daily or weekly injectable form. In Spain, semaglutide in particular is also available in the form of tablets.
According to Dr. W. Timothy Garvey, from the Department of Nutritional Sciences at the University of Alabama (USA), and director of the latest semaglutide study, it is currently the most effective drug for treating obesity, and even in competition with other more invasive methods such as bariatric surgery.
In order to get this slimming pill approved as an anti-obesity drug, semaglutide has shown an average weight loss of over 15% in clinical trials when applied to a lifestyle program healthy. Such weight loss has been shown to be sufficient to treat or prevent a wide range of complications secondary to obesity, according to Garvey.
The results will be announced at the annual meeting of the European Association for the Study of Diabetes later this month in Stockholm, Sweden.